ATAXIN-1与其本源复合体中的抑制剂Capicua相互作用,导致SCA1神经病理
Yung C Lam1, Aaron B Bowman, Paymaan Jafar-Nejad
1Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.
Cell
|December 28, 2006
概括
1型脊髓小脑性动症 (SCA1) 源于扩大的ATAXIN-1 (ATXN1). 这项研究揭示了ATXN1的存在.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 分子遗传学 分子遗传学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 1型脊髓脑动症 (SCA1) 是一种神经退行性疾病,与ATXN1蛋白中的多重谷氨胺通道扩张有关.
- 在SCA1病变发生过程中,一个关键的问题是扩展的ATXN1是否会通过新的相互作用或增强的野生类型功能引起毒性.
研究的目的:
- 研究野生型和扩展型ATAXIN-1 (ATXN1) 的蛋白相互作用.
- 为了确定Capicua在ATXN1-介导的神经毒性中在Sinocerebellar ataxia type 1 (SCA1) 中的作用.
主要方法:
- 来自小鼠大脑的可溶性蛋白质复合物的分析.
- 在Drosophila和哺乳动物细胞中ATXN1与Capicua结合的体外和体内研究.
- 评估S776A突变对ATXN1-Capicua相互作用和神经毒性的影响.
主要成果:
- 野生型和扩展型ATXN1都与转录抑制剂Capicua形成了大而稳定的复合体.
- ATXN1直接结合并调节Capicua活动,影响其稳定状态水平.
- 防止ATXN1神经毒性的突变 (S776A) 显著减少了它与Capicua的关联.
结论:
- ATXN1的原生功能涉及与Capicua的相互作用,调节其抑制活性.
- SCA1的神经病理似乎取决于ATXN1的本地相互作用的增强,特别是与Capicua,而不是异常的新相互作用.
- 这些发现为ATXN1功能和SCA1.1背后的分子机制提供了关键的见解.
相关概念视频
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...